key: cord-0791018-ne9ww9mp
authors: Ergün, Bişar; Ergan, Begüm; Sözmen, Melih Kaan; Küçük, Murat; Yakar, Mehmet Nuri; Cömert, Bilgin; Gökmen, Ali Necati; Yaka, Erdem
title: New‐onset atrial fibrillation in critically ill patients with coronavirus disease 2019 (COVID‐19)
date: 2021-08-16
journal: J Arrhythm
DOI: 10.1002/joa3.12619
sha: 9b709e32d1f215e78a539a2b6d41b5e47b4336ac
doc_id: 791018
cord_uid: ne9ww9mp

BACKGROUND: Mortality in critically ill patients with coronavirus disease 2019 (COVID‐19) is high, therefore, it is essential to evaluate the independent effect of new‐onset atrial fibrillation (NOAF) on mortality in patients with COVID‐19. We aimed to determine the incidence, risk factors, and outcomes of NOAF in a cohort of critically ill patients with COVID‐19. METHODS: We conducted a retrospective study on patients admitted to the intensive care unit (ICU) with a diagnosis of COVID‐19. NOAF was defined as atrial fibrillation that was detected after diagnosis of COVID‐19 without a prior history. The primary outcome of the study was the effect of NOAF on mortality in critically ill COVID‐19 patients. RESULTS: NOAF incidence was 14.9% (n = 37), and 78% of patients (n = 29) were men in NOAF positive group. Median age of the NOAF group was 79.0 (interquartile range, 71.5‐84.0). Hospital mortality was higher in the NOAF group (87% vs 67%, respectively, P = .019). However, in multivariate analysis, NOAF was not an independent risk factor for hospital mortality (OR 1.42, 95% CI 0.40‐5.09, P = .582). CONCLUSIONS: The incidence of NOAF was 14.9% in critically ill COVID‐19 patients. Hospital mortality was higher in the NOAF group. However, NOAF was not an independent risk factor for hospital mortality in patients with COVID‐19.

It was shown that hospitalized patients with COVID-19 with atrial fibrillation (AF) and atrial flutter history had a higher mortality rate than those without AF. 7 However, the data for the incidence of new-onset AF (NOAF) in patients with COVID-19 are limited. The most common type of new arrhythmia in infection was AF, and AF was mostly detected in the ICU setting. 8, 9 In a study, NOAF incidence was 7.5% in patients hospitalized for COVID-19. 10 The ICU mortality in COVID-19 is 35.5%, 11 and the rate increases up to 45% in patients who require invasive mechanical ventilation. 12 Several other risk factors for mortality were defined such as older age, male sex, higher body mass index (BMI), elevated levels of D-dimer, lactate, and presence of active cancer, coronary artery disease, liver, and kidney dysfunction in patients admitted to ICU. 13, 14 This study aimed to determine the incidence of NOAF development in critically ill COVID-19 patients, identify possible risk factors for NOAF development, and evaluate its effect on mortality. 

The NOAF group consisted of patients who had their first AF attack after hospitalization for COVID-19. NOAF was defined as either (1) AF ≥1 h in duration, as noted by bedside telemetry; (2) AF <1 h in duration, but captured on the electrocardiogram, or (3) AF initiating pharmacologic therapy or electrical cardioversion according to literature. 15 12-derivation electrocardiography (ECG) record is routinely obtained from all patients at the time of admission to the ICU in our center (number of beds = 30). All beds are monitored in the ICU, and nurse to bed ratio was 1/2. When there was either monitor image/alarm or examination findings that are compatible with AF, an immediate 12-derivation ECG was recorded and the intensivist and/or cardiologist confirmed the definite NOAF diagnosis. Medical and/or electrical cardioversion, if required, was decided based on the clinical condition of the patients.

The cardiac injury was defined as an increase in high-sensitive (HS) troponin I levels above the 99th-percentile upper reference limit. 2 Acute kidney injury (AKI) was identified according to the Kidney Disease: Improving Global Outcomes definition. 16 Ventilatorassociated pneumonia (VAP) was defined as pneumonia occurring more than 48 h after patients have been intubated and received mechanical ventilation. VAP was identified using a combination of positive culture results from the respiratory specimen, clinical, laboratory, and radiological findings. 17 Acute myocardial infarction was defined according to the fourth universal definition of myocardial infarction, 18 and cardiologist confirmation. 

The primary outcome of the study was whether the presence of NOAF is a risk factor for mortality in COVID-19. Secondary outcomes were the risk factors associated with the development of NOAF. All categorical variables are expressed as numbers and percentages, and continuous variables were expressed as the median and interquartile range (IQR). Categorical variables between groups were compared with chi-square or Fisher's exact test, continuous variables were compared with Mann-Whitney U-test. The independent effect of NOAF on hospital mortality was assessed with multivariate logistic regression analysis. To build the model, a purposeful selection method was used to select a subset of covariates that were considered clinically important, adjusting for confounders and statistical significance. An adjusted odds ratio (OR) and a 95% confidence interval (CI) were reported for each independent factor. A two-tailed P-value of <.05 was considered statistically significant. Statistical analysis was performed using SPSS (Statistical Package for the Social Sciences Version 24, IBM Corp., Armonk, NY, USA). 

It was found that the median B-type natriuretic peptide (BNP) level was higher in the NOAF positive group compared to the NOAF negative group (366 [112-850] vs 96 pg/mL, respectively, P = .001). The BNP levels of 114 (46.0%) patients were >100 pg/ mL, which is the upper limit of the normal range, and the proportion of NOAF positives was higher than the rate of NOAF negatives The cardiac injury was detected in 159 (64.1%) patients.

Although the rate for cardiac injury was higher in the NOAF positive group than the NOAF negative group it did not reach a statistical significance (75.7%, vs 62.1%, respectively; P = .13). Acute myocardial infarction was detected in 10 patients (4.0%) after the COVID-19 diagnosis. None of these patients had NOAF. Pulmonary embolism (PE) was detected in 6 patients (2.4%) after the COVID-19 diagnosis. It was shown that the incidental PE rate was higher in the NOAF positive group than the NOAF negative group (8.1% vs 1.4%, respectively; P = .045). All the PE attacks were diagnosed before the NOAF attack.

AKI and VAP were more frequent in the NOAF positive group than the NOAF negative group (for AKI 70.3%, vs 51.7%, respectively; P = .048 and for VAP 54.1%, vs 35.5%, respectively; P = .04). The percentage of patients with secondary bacterial infection was significantly higher in the NOAF positive group than the NOAF negative group (75.7% vs 51.7%, respectively; P = .007). WBC, x 10 3 /µL 11.1 (7.9-15.1) 11.0 (7.5-16.7) 11.2 (7.9-15.0) .96

Neutrophil, x 10 3 /µL 9.6 (6.8-13.9) 9.5 (6.4-14.1) 9.6 (6.8-14.0) .87

Lymphocyte, x 10 3 /µL 0. Tested on the day of ICU admission. f Laboratory upper limit of BNP (100 pg/mL). In this study, hospital mortality was 70.1% (n = 174). Statistically significant variables for hospital mortality are reported in Table 2 .

Multivariable analysis ( 

This retrospective cohort study has two important results. First, NOAF incidence in critically ill COVİD-19 patients is 14.9%. NOAF risk was associated with older age and the presence of comorbidities. Second, hospital mortality increases in critically ill COVID-19 patients with NOAF.

The incidence of NOAF in surgical and medical mixed ICUs varied between 1.7% and 29.5% in the literature. 19 However, the occurrence of NOAF in critically ill COVID-19 patients has not been well described. Some studies have reported atrial arrhythmia and AF episodes in patients with COVID-19, 8, 9, 20 and NOAF has mainly occurred in critically ill patients. 8, 9 However, in these studies, data of NOAF are limited. NOAF rate was separately reported in one study and incidence of NOAF was 7.5% (n = 12) of 160 patients who were hospitalized for COVID-19 infection. 10 We have found that the incidence of NOAF in critically ill patients is 14.9%; hence the risk of developing NOAF in critically ill patients with severe covid-19 infection is relatively high.

Cardiac involvement, such as myocardial injury, myocardial ischemia, myocarditis, cardiogenic shock, acute cor pulmonale, thrombotic complications, and arrhythmia were previously reported in patients with COVID-19. 3, 21 It is considered that myocarditis is caused by inflammatory infiltrates damaging the myocardium and myocardial injury without acute ischemic event. 22 It has been reported that serious infection, severe tissue inflammation, hypoxia, and electrolyte abnormalities may trigger atrial and ventricular arrhythmia. 23 However, the etiology of cardiac arrhythmias in COVID- 19 has not yet been fully clarified. The most proposed mechanisms are hypoxemia because of acute respiratory distress, increased inflammatory response, and myocardial damage caused by cytokine crisis, increase in catecholamine, direct viral endothelial damage, acid-base, and electrolyte abnormalities. 24, 25 In this study, the PaO2/FiO2 ratio was lower in patients with NOAF than in patients without NOAF, but there was no statistically significant difference. More comprehensive studies are required to investigate the effect of hypoxemia on NOAF development in patients with COVID-19.

The incubation period for COVID-19 is median 5-6 days; however, it can be up to 14 days. 26, 27 This relatively short period is not sufficient for developing fibrosis-related conditions; therefore, it is expected that this short incubation period does not increase the risk of AF. 25 Since patients with COVID-19 who developed AF were older and had comorbidities, such as hypertension, 10, 28 it was considered that COVID-19 infection triggers NOAF in the presence of a previously predisposing factor. 25 Our findings are also consistent with these reports as patients who had NOAF in this study were older and had higher CCI as well. It was observed that NOAF was developed during the first days of acute illness (median day 3.0 [0.0-10.0]) which is similar to previously reported. 29, 30 To date, the acute cardiac injury was observed between 12.0% and 29.8% in patients with COVID-19. [2] [3] [4] 31, 32 The frequency of cardiac injury was 64.1% in our study and this rate was higher than previously reported. We believe that the higher rate of cardiac injury was probably due to the population studied. times higher in patients with severe COPD than in non-COPD patients. 35 NOAF prevalence was between 4.7% and 15% in stable patients with COPD, 36 and around 20%-30% in severe patients with COPD. 37 Impaired gas exchange and oxidative stress were considered the possible causes triggering NOAF in COPD. 38 Respiratory failure and hypoxemia because of COVID-19 may have increased the risk of NOAF in this specific group of patients.

In our study, it was also found that NOAF was mostly detected in patients who developed secondary bacterial infections in ICU follow-ups. AF was reported to be the most common arrhythmia in patients with sepsis 39 and was also associated with increased mortality in this group of patients. 40 The use of vasopressor also contributes to NOAF development in septic shock patients. 34 It was observed that PE rate was higher in the NOAF positive group than the NOAF negative group in this cohort. 16 .5% in COVID-19 infection, which is relatively high. 41 PE-induced ventricular dysfunction and increased atrial tension may be a factor for triggering AF. 42 New AF attacks have deleterious effects, such as increasing heart rate, causing irregular rhythm and losses in atrial systole, and neurohormonal activation. For this reason, NOAF development can further complicate critical disease or may limit response to therapy. 43 Cardiac output may decrease because of loss of atrial systole and tachycardia, and acute heart failure may develop. 43, 44 It was found in some studies that NOAF development correlate with the severity of critical illness. 45 Although no independent relations were detected in some previous studies between NOAF and hospital mortality, 46-48 some studies found that NOAF was associated with increased hospital mortality regardless of the severity of the critical disease. 29, 49 However, in this study, NOAF was not an independent risk factor for hospital mortality in multivariate analysis.

This study has several limitations. First, the results are from a single center and could not be generalized. Second, it is impossible to differentiate whether NOAF developed due to COVID-19 related cardiac involvement or due to critical illness itself. Third, we could not analyze long-term consequences of NOAF. However, the study has some strengths. We think that our findings are valuable as NOAF development in critical COVID-19 studied to a lesser extent. Second, the diagnostic accuracy for NOAF was high as the diagnosis was confirmed by an intensivist/cardiologist in all cases.

Older patients with comorbidities have a high risk of developing NOAF in severe COVID-19 infection. The prognostic significance of NOAF on ICU and hospital mortality in these patients merits further research. 

A novel coronavirus from patients with pneumonia in China

Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China

Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)

Cardiac injury and outcomes of patients with COVID-19 in

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusinfected pneumonia in Wuhan, China

Clinical characteristics of Covid-19 in New York City

Outcomes and mortality associated with atrial arrhythmias among patients hospitalized with COVID-19

Atrial arrhythmias in COVID-19 patients

COVID-19 and cardiac arrhythmias

New-onset atrial fibrillation during COVID-19 infection predicts poor prognosis

Mortality in patients admitted to intensive care with COVID-19: an updated systematic review and meta-analysis of observational studies

Case fatality rates for patients with COVID-19 requiring invasive mechanical ventilation

Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: initial report of the international RISC-19-ICU prospective observational cohort

Factors associated with death in critically Ill patients with coronavirus disease 2019 in the US

New-onset atrial fibrillation and associated outcomes and resource use among critically ill adults -a multicenter retrospective cohort study

Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury

Ventilator-associated pneumonia: new definitions

Fourth universal definition of myocardial infarction

New-onset atrial fibrillation in adult critically ill patients: a scoping review

New-onset cardiac arrhythmias during COVID-19 hospitalization

Extrapulmonary manifestations of COVID-19

Molecular biology and pathogenesis of viral myocarditis

Overview of basic mechanisms of cardiac arrhythmia

Cardiac and arrhythmic complications in patients with COVID-19

COVID-19 associated atrial fibrillation: Incidence, putative mechanisms and potential clinical implications

A familial cluster of infection associated with the 2019 novel coronavirus indicating possible personto-person transmission during the incubation period

The incubation period of coronavirus disease 2019 (CoVID-19) from publicly reported confirmed cases: estimation and application

Low prevalence of arrhythmias in clinically stable COVID-19 patients

New-onset atrial fibrillation in critically ill patients and its association with mortality: a report from the FROG-ICU study

Incidence and predictors of new-onset atrial fibrillation in septic shock patients in a medical ICU: data from 7-day Holter ECG monitoring

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Cardiovascular comorbidities, cardiac injury, and prognosis of COVID-19 in New York City

Prevalence, outcomes, and risk factors of new-onset atrial fibrillation in critically ill patients a systematic review

Risk factors for new-onset atrial fibrillation on the general adult ICU: a systematic review

Relation of chronic obstructive pulmonary disease to atrial and ventricular arrhythmias

Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study

Contribution of the environment and comorbidities to chronic obstructive pulmonary disease phenotypes

Atrial fibrillation in the acute, hypercapnic exacerbations of COPD

Severe sepsis and cardiac arrhythmias

Clinical characteristics and outcomes of septic patients with new-onset atrial fibrillation

Pulmonary embolism and deep vein thrombosis in COVID-19: a systematic review and meta-analysis

Venous thromboembolism increases the risk of atrial fibrillation: the Tromso study

Prognostic impact of restored sinus rhythm in patients with sepsis and newonset atrial fibrillation

Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham heart study

Incidence and risk factors of atrial fibrillation in a surgical intensive care unit

Atrial fibrillation and mortality in critically ill patients: a retrospective study

Incidence and prognosis of sustained arrhythmias in critically III patients

Epidemiology and outcome of new-onset atrial fibrillation in the medical intensive care unit

Atrial fibrillation is an independent predictor of mortality in critically ill patients

How to cite this article

New-onset atrial fibrillation in critically ill patients with coronavirus disease 2019 (COVID-19)